Full Press Release Details
| Dr. Reddy s Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. | ||
| CIN : L85195TG1984PLC004507 | ||
| Tel :+91 40 4900 2900 | ||
| Fax :+91 40 4900 2999 | ||
| Email: mail@drreddys.com | ||
| www.drreddys.com |
| Surveillance Department | National Stock Exchange of India Ltd. | |||||
| BSE Limited | Exchange Plaza | |||||
| Dalal Street, Fort | Bandra-Kurla Complex, Bandra (East), | |||||
| Mumbai 400 001 | Mumbai 400 051 | |||||
| Fax Nos.: | 022-22723121 / 22723719 / | Fax Nos.: | 022-26598120/26598237/ | |||
| 22722037 / 22722039 | 26598238 | |||||
| Scrip Code: 500124 | Scrip Code: DRREDDY-EQ |
email dated April 3, 2017
Sub: Clarification on news item appeared on CNBC TV18 dated April 3, 2017 captioned US FDA started
Srikakulam inspection on March 27, 2017. No major observation from US FDA yet on Srikakulam plant.
This is with reference to your email dated
April 3, 2017, seeking clarification on the above subject.
In this regard, please note that the reports being flashed by some media are
speculative and unverified. The Company has not issued any statement as the audit is still in progress.
We regularly inform all concerned on
material events and presently do not have any other information which is material to the Company s operations or consolidated results.
movement in price of Company s scrip is completely market driven and hence the Company has no comments to offer on share price movement.
your information and record.
CC: New York Stock Exchange Inc. (Stock Code: RDY)